fragment
spike
protein
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
contain
epitop
capabl
recogn
convalesc
sera
sar
patient
vaccin
mice
recombin
induc
ab
sarscov
although
titer
rel
low
present
studi
fusion
protein
link
fragment
residu
murin
calreticulin
crt
prokaryot
express
system
creat
compar
target
antigen
alon
recombin
fusion
product
much
improv
hydrophil
immunogen
igg
ab
balbc
mice
subcutan
immun
substanti
higher
titer
approxim
fivefold
furthermor
fusion
protein
alon
propos
fragment
crt
effect
molecular
adjuv
capabl
enhanc
target
agspecif
humor
respons
celldepend
independ
manner
fusion
protein
potenti
candid
vaccin
sarscov
infect
former
contain
receptorbind
domain
respons
viral
bind
receptor
target
cell
former
studi
shown
protein
major
antigen
recogn
protect
neutral
antibodi
patient
previous
express
fragment
protein
e
coli
demonstr
sar
patient
mount
earli
strong
humor
respons
polypeptid
howev
solubl
immunogen
rel
poor
compromis
use
vaccin
candid
calreticulin
express
mainli
er
cell
contain
amino
acid
fold
three
domain
lectinlik
n
domain
residu
prolin
rich
p
domain
residu
calciumbind
c
domain
residu
review
refer
one
key
molecular
chaperon
er
well
homeostat
control
amount
cytosol
er
calcium
addit
crt
recogn
one
heat
shock
protein
potent
immunobiolog
activ
recent
shown
recombin
fragment
murin
crt
cover
partial
n
p
domain
potent
activ
b
cell
macrophag
via
toll
like
pathway
fuse
egfp
greatli
improv
humor
respons
egfp
balbc
cell
defici
nude
mice
use
dna
vaccin
encod
fusion
protein
crt
target
antigen
tumor
antigen
n
protein
sarscov
bacillu
anthraci
protect
antigen
domain
iv
previou
investig
also
observ
crt
function
molecular
adjuv
present
studi
prepar
solubl
recombin
fusion
protein
observ
much
better
immunogen
alon
femal
balbc
balbcnu
mice
week
age
obtain
academi
militari
medic
scienc
beij
china
hous
specif
pathogenfre
barrier
facil
mice
immun
sc
recombin
protein
pb
base
tail
mous
blood
collect
tail
bleed
differ
time
point
post
immun
sera
kept
c
use
high
fidel
taq
dna
polymeras
purchas
takara
biotech
shiga
japan
restrict
enzym
ligas
invitrogen
carlsbad
ca
usa
kit
dna
extract
purif
qiagen
hilden
germani
e
coli
strain
stratagen
la
jolla
ca
usa
ninitrilotriacet
acid
ninta
resin
novagen
darmstadt
germani
cell
transfect
reagent
vigor
biotech
beij
china
prepar
express
plasmid
encod
perform
previous
describ
digest
hindiii
xhoi
promega
madison
wi
usa
crt
dna
fragment
clone
hindiii
xhoi
site
gener
plasmid
construct
confirm
dna
sequenc
express
purif
recombin
protein
essenti
previous
describ
briefli
e
coli
cell
harbor
plasmid
cultur
medium
contain
kanamycin
c
cell
densiti
reach
optic
densiti
iptg
sigmaaldrich
st
loui
mo
usa
ad
final
concentr
mm
bacteria
cultur
hr
c
cultur
harvest
centrifug
cell
pellet
suspend
ml
bind
buffer
mm
nacl
mm
trishcl
mm
imidazol
ph
sonic
puls
paus
w
time
lyse
cell
centrifug
g
min
c
supernat
incub
ml
ni
sepharos
ge
healthcar
uppsala
sweden
c
hr
sepharos
pour
column
wash
ml
wash
buffer
mm
nacl
mm
trishcl
mm
imidazol
ph
recombin
protein
elut
elut
buffer
mm
nacl
mm
trishcl
mm
imidazol
ph
final
product
dialyz
pb
ph
store
c
use
elisa
perform
accord
protocol
previous
describ
briefli
elisa
plate
coat
c
overnight
carbon
buffer
ph
well
incub
bsa
pb
hr
c
wash
five
time
pbst
serum
sampl
immun
mice
dilut
dilut
buffer
bsa
pb
dilut
ad
well
plate
incub
min
c
wash
pbst
plate
incub
hrplabel
goat
antimous
igg
antibodi
southern
biotech
birmingham
al
usa
dilut
dilut
buffer
hr
c
opd
substrat
well
ad
five
wash
pbst
incub
room
temperatur
h
solut
ad
well
stop
reaction
optic
densiti
immedi
read
nm
bone
marrow
flush
femora
tibia
balbc
mice
incub
start
concentr
cellsml
medium
flat
bottom
plate
falcon
oxnard
ca
usa
c
co
hr
nonadher
cell
remov
recombin
mous
gmcsf
rmgmcsf
peprotech
ec
london
uk
ad
cultur
ngml
day
half
medium
replac
fresh
medium
contain
rmgmcsf
day
adher
cell
harvest
bonemarrowderiv
immatur
dc
examin
microscop
also
flow
cytometri
express
indirect
immunofluoresc
stain
cell
collect
wash
bsa
sigma
st
loui
mo
usa
pb
pellet
cell
tube
incub
min
c
phycoerythrinconjug
rat
antimous
also
fitcconjug
ab
mous
fitcconjug
isotyp
control
ab
biolegend
franklin
lake
nj
usa
wash
cell
subject
analysi
use
fluorescenceactiv
cell
sorter
facscan
bectondickinson
rutherford
nj
usa
experi
repeat
least
three
time
result
express
mean
sd
mean
statist
analysi
perform
use
independentsampl
ttest
twosid
pair
ttest
group
use
spss
program
spss
chicago
il
usa
differ
consid
statist
signific
p
prepar
express
vector
encod
murin
respect
describ
previous
present
studi
new
dna
construct
name
encod
fusion
protein
murin
histidin
tag
creat
three
recombin
protein
success
express
e
coli
illustr
figur
follow
iptg
induct
highli
solubl
polypeptid
present
lysat
e
coli
cell
harbor
whilst
less
solubl
mainli
express
inclus
bodi
bacteria
fusion
protein
found
cell
lysat
inclus
bodi
transduc
e
coli
cell
three
recombin
product
purifi
use
nicolumn
homogen
result
product
assess
sdspage
gel
electrophoresi
fig
initi
immunogen
evalu
recombin
fusion
protein
carri
compar
abil
elicit
ab
vivo
alon
mixtur
equal
proport
figur
show
fusion
protein
far
effect
immunogen
induc
igg
respons
balbc
mice
detail
analysi
igg
ab
thu
produc
carri
serum
sampl
balbc
mice
five
per
group
day
post
sc
immun
assay
elisa
serum
ab
titer
group
approxim
fivefold
higher
group
fig
target
agspecif
igg
group
isotyp
whilst
specif
hardli
detect
sera
mice
fig
c
previous
demonstr
group
abl
activ
b
cell
trigger
ig
product
igg
class
switch
absenc
cell
help
vitro
vivo
interest
know
whether
also
induc
igg
tcelldefici
mice
balbcnu
mice
vaccin
sc
either
monitor
serum
igg
ab
fusion
protein
success
induc
igg
product
nude
mice
fig
potent
adjuvant
partial
explain
direct
activ
effect
b
lymphocyt
howev
possibl
way
enhanc
target
agspecif
humor
lrespons
vivo
adjuv
typic
character
abil
activ
profession
apc
dc
macrophag
rather
b
cell
lp
regfp
hr
analyz
flow
cytometri
express
regard
marker
dc
matur
illustr
figur
percentag
cell
group
treat
consider
higher
regfp
control
group
thu
confirm
potent
activ
murin
dc
support
fact
well
regfp
abl
induc
product
dc
vitro
data
shown
abil
activ
dc
due
endotoxin
contamin
recombin
protein
use
studi
pass
polymyxin
b
agaros
remov
endogen
lp
could
come
e
coli
system
newli
emerg
pathogen
srascov
avian
influenza
virus
major
concern
public
health
today
develop
effect
vaccin
adjuv
infecti
agent
urgent
need
result
report
herein
show
fusion
protein
exhibit
much
potent
immunogen
alon
term
elicit
igg
respons
vivo
note
howev
whether
ab
exhibit
neutral
effect
sarscov
infect
remain
test
use
either
live
viru
pseudoviru
system
physic
linkag
necessari
improv
immunogen
mixtur
immunogen
alon
fig
anoth
advantag
immunogen
better
hydrophil
prepar
renatur
step
necessari
nicolumn
purif
result
product
maintain
rel
low
concentr
order
avoid
protein
aggreg
precipit
contrast
renatur
step
necessari
prepar
final
product
less
like
form
aggreg
pb
although
previou
work
show
abl
activ
b
cell
macrophag
vitro
data
dc
activ
allow
panoram
view
molecular
mechan
underli
extraordinari
adjuvant
prokaryot
express
solubl
calreticulin
fragment
also
import
mention
addit
stimulatori
effect
b
cell
dc
also
induc
helper
cell
respons
mice
previou
studi
use
drain
lymph
node
cell
balbc
mice
sc
immun
abl
establish
highli
sensit
crtspecif
helper
cell
line
manuscript
prepar
base
upon
observ
propos
recombin
crt
may
function
molecular
adjuv
sever
differ
pathway
may
result
synergist
effect
vivo
firstli
apc
known
express
differ
receptor
eg
crt
would
facilit
effici
captur
uptak
crtlink
antigen
secondli
solubl
crt
directli
activ
dc
fig
macrophag
therebi
lead
effici
antigen
process
present
thirdli
crt
fusion
protein
function
carrier
protein
activ
helper
cell
capabl
provid
cognat
help
antigenspecif
b
cell
final
crt
portion
fusion
protein
directli
activ
b
cell
trigger
igg
class
switch
even
absenc
cell
help
ref
fig
genom
mani
virus
eg
sarscov
influenza
virus
undergo
substanti
mutat
diminish
cell
epitop
viral
protein
result
escap
viru
immun
detect
lymphocyt
scenario
abil
vaccin
induc
igg
respons
host
defici
cognat
helper
cell
valuabl
calreticulin
wide
express
selfantigen
use
molecular
adjuv
inevit
embed
possibl
trigger
exacerb
immunopatholog
reaction
vivo
previou
investig
observ
increas
concentr
crtspecif
serum
igg
ab
patient
system
lupu
erythematosu
rheumatoid
arthriti
howev
unclear
whether
ab
particip
patholog
damag
host
function
part
immunoregulatori
network
employ
immun
differ
strain
mice
rat
rabbit
without
freund
adjuv
high
titer
igg
ab
obtain
anim
accompani
sign
autoimmun
disord
data
shown
one
experi
balbc
mice
remain
healthi
month
four
dose
sc
immun
data
shown
argu
possibl
recombin
crt
caus
autoimmun
damag
vivo
previou
investig
exploit
adjuvant
crt
use
molecular
adjuv
dna
vaccin
cheng
colleagu
found
intraderm
immun
dna
vaccin
encod
fusion
protein
crt
crt
fragment
tumor
antigen
effici
elicit
cell
protect
tumor
mice
park
cowork
prepar
dna
vaccin
encod
fusion
protein
crt
bacillu
anthraci
protect
antigen
domain
iv
show
much
enhanc
antibodi
respons
target
ag
kim
colleagu
also
demonstr
dna
vaccin
encod
crt
link
n
protein
sarscov
capabl
gener
strong
nspecif
humor
cellular
immun
note
howev
protein
express
dna
vaccin
may
retain
endoplasm
reticulum
golgi
synthesi
thu
limit
abil
induc
antibodi
respons
moreov
intracellularli
express
crt
may
effici
solubl
extracellular
crt
exert
apc
condit
activ
b
cell
vivo
nucleocapsid
protein
anoth
major
structur
protein
sarscov
capabl
elicit
strong
humor
cellular
immun
respons
patient
experiment
anim
unlik
protein
contain
neutral
epitop
n
protein
induc
neutral
ab
vivo
locat
insid
viral
particl
hand
e
protein
sarscov
play
synergist
role
viral
infect
ab
viral
protein
thought
synergist
effect
combat
infect
c
societi
blackwel
publish
asia
pti
ltd
sarscov
thu
recombin
fusion
polypeptid
contain
major
b
cell
epitop
e
protein
sarscov
may
compris
favor
vaccin
design
conclus
sever
advantag
includ
immunogen
stabil
solut
simplic
product
given
abl
activ
human
peripher
blood
mononuclear
cell
vitro
crt
fragment
could
exploit
molecular
adjuv
prepar
sarscov
vaccin
human
